Uncategorized Archives - PsychedelicNewsWire (PNW)

TuesdayJul 09, 2024 10:00 am

Study Highlights How Psilocybin Impacts Auditory Cortex, Causing Perception Changes

New research has generated new insights into how psilocybin influences the auditory cortex in mice models. Psilocybin is a natural psychedelic compound that is found in more than 200 species of fungi. The compound is known to induce altered states of consciousness when ingested, including changes in cognition, mood and perception. Various studies have investigated the compound’s effectiveness in treating mental-health disorders, including anxiety and depression. While its therapeutic potential is evident, the exact mechanisms via which this psychedelic alters perception and brain function aren’t well understood. Prior studies have shown that psilocybin alters activity patterns in the brain and…

TuesdayJun 25, 2024 10:00 am

Analyzing Possible Industry Implications of FDA Advisory Panel Decision on MDMA

About a week ago, an advisory committee to the U.S. Food and Drug Administration (FDA) rejected evidence supporting the approval of MDMA as an alternative treatment for post-traumatic stress disorder (PTSD). This is a deflating moment for many in psychedelic research who have, for years, conducted trials on the drug in an effort to gain approval for commercial distribution. The application reviewed by the advisory committee was presented by Lykos Therapeutics, which concluded phase 2 and 3 trials investigating the effectiveness of MDMA-assisted therapy in managing post-traumatic stress disorder. In their report, the advisors revealed that they went through the…

ThursdayMay 23, 2024 11:15 am

4th Annual Psychedelic Therapeutics and Drug Development Conference Comes to Boston, MA

Researchers and leaders in academia, industry, the non-profit sector, and government organizations are invited to attend the 4th Annual Psychedelic Therapeutics and Drug Development Conference being held May 23-24, 2024, in Boston, MA. The conference focuses on discussing the hurdles as well as challenges in the research and development of psychedelics for various health conditions. Join the experts for this two-day conference that involves exploration, learning, discussion, and networking. Specific areas of discussion will include: Targets for novel drug development Toxicology studies and considerations The dosage debate and new evidence Second generation psychedelic drug design FDA regulatory guidance The speaker…

ThursdayApr 18, 2024 10:00 am

Therapist Explains What Psychedelics Do, What Talk Therapy Can’t

Interest in the use of psychedelics in therapy has increased over the last couple of years, with researchers finding that drugs such as psilocybin, LSD and ketamine may be useful in the treatment of different mental-health conditions. According to one therapist, psychedelics are drugs that enable the dissolution of the individual ego. This is the objective of many spiritual traditions, where one realizes that they aren’t an individual island living a separate life but a smaller cog in a huge machine. By the aforementioned definition, psychedelics include ayahuasca, DMT, ketamine, psilocybin and LSD. It is important to note MDMA is…

ThursdayMar 21, 2024 10:00 am

Study Suggests Psilocybin Mushrooms Trigger Enhanced Benefits on Brain Compared to Synthetic Versions

New research suggests that hallucinogenic mushrooms that contain psilocybin may be useful in the treatment of conditions such as anxiety, post-traumatic stress disorder and obsessive-compulsive disorders. Professor Bernard Lerer, the author of the study, stated that researchers were interested in psychedelics’ potential in managing treatment-resistant psychiatric disorders, including post-traumatic stress disorder, depression and even schizophrenia. Lerer, a psychiatry professor and the director of Hebrew University’s Hadassah BrainLabs Center for Psychedelic Research, explained that many reports had proposed that using extracts from mushrooms that contain psilocybin could have effects that were quantitatively and qualitatively different from chemical psilocybin, which is what…

ThursdayMar 14, 2024 11:00 am

How Psychedelics Could Enable Soldiers Beat Trauma

Data from Veterans Affairs estimates that more than 120,000 veterans in the United States have died by suicide. Many more in America and other parts of the globe struggle with post-traumatic stress disorder as conflicts rear their heads globally. In Ukraine, the ministry of health estimates that close to four million individuals are living with post-traumatic stress disorder. To help manage this, many have turned to psychedelics, and for good reason. Last month, the country’s special parliamentary commission voted to set up a working group that would investigate the effectiveness of MDMA-assisted therapy on post-traumatic stress disorder. In a statement,…

FridayJan 19, 2024 3:18 pm

Reintroduced NJ Bill Seeks to Legalize Psilocybin

The state of New Jersey may soon legalize the recreational and therapeutic use of psilocybin mushrooms, following the reintroduction of a measure that was withdrawn in 2023 for revision. The measure, called the Psilocybin Behavioral Health Access and Services Act, concentrates on mental health. Psilocybin is a naturally occurring psychedelic compound found in hallucinogenic mushrooms. According to research, this compound is metabolized in the body to psilocyn and can penetrate the central nervous system. The measure was tabled at the state Senate again last week and has strong support, particularly from Senate President Nick Scutari, who originally sponsored the recreational…

WednesdayJan 10, 2024 4:06 pm

Exploring How Psilocybin Affects Self-Perception

Researchers from Montclair State University recently dived into multitudes of social media posts to try and understand how psilocybin, the main psychedelic element within magic mushrooms, affects an individual’s self-perception. Published in the “Journal of Psychedelic Studies,” the recent study sought to understand how psychedelics, specifically psilocybin, affect self-perception and self-recognition. Psychedelics such as psilocybin have attracted considerable attention in recent years, thanks to a growing body of scientific studies and anecdotal reports of their efficacy against a myriad of mental conditions. Scientific literature on psychedelics states that they can treat the symptoms of debilitating mental disorders, including post-traumatic stress…

FridayJan 05, 2024 2:00 pm

An Analysis of Recent FDA Warnings About Compounded Ketamine

The U.S. Food and Drug Administration (FDA) issued two warnings regarding compounded ketamine use on Feb. 16, 2022, and a year and a half later on Oct. 10, 2023. Ketamine is a dissociative anesthetic that is typically used to induce loss of consciousness and treat pain in both humans and animals. It has some hallucinogenic properties and is often called a dissociative anesthetic hallucinogen because it can make patients and recreational users feel detached from physical pain and the environment. Ketamine can also induce amnesia, a sense of sedation and immobility, making it the drug of choice for bad actors…

TuesdayDec 19, 2023 9:00 am

DEA Renews Efforts to Ban Psychedelics Despite Backlash in 2022

Last week, the Drug Enforcement Administration (DEA) suggested that DOC and DOI be classified under Schedule I of the Controlled Substances Act in its latest notice. DOC (2,5-dimethoxy-4-chloroamphetamine) and DOI (2,5-dimethoxy-4-iodoamphetamine) are both psychedelic drugs of the amphetamine and phenethylamine chemical classes. In its latest notice, the DEA stated that the medical and scientific basis for suggesting the ban was that these hallucinogens had no known medical value and a high potential for abuse. This is despite the fact that the agency possesses no evidence demonstrating a high abuse potential or directly linking the compounds to severe health events. In…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized